{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:01:26Z","timestamp":1789052486127,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ejca.2017.05.041","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T16:30:20Z","timestamp":1498581020000},"page":"128-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":230,"special_numbering":"C","title":["Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0528-3084","authenticated-orcid":false,"given":"D.","family":"Makarious","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Horwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.I.G.","family":"Coward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.05.041_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/1078155216687389","article-title":"Pembrolizumab-induced myasthenia gravis: a fatal case report","author":"March","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ejca.2017.05.041_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","article-title":"Myasthenia triggered by immune checkpoint inhibitors: new case and literature review","volume":"27","author":"Gonzalez","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ejca.2017.05.041_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","article-title":"Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients","volume":"27","author":"Nguyen","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2017.05.041_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.05.041_bib5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2017.05.041_bib6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2017.05.041_bib7","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1002\/mus.25496","article-title":"A case of new onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma","volume":"55","author":"Alnahhas","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejca.2017.05.041_bib8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mus.25163","article-title":"Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer","volume":"54","author":"Polat","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejca.2017.05.041_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mus.25212","article-title":"Benign form of myasthenia gravis after nivolumab treatment","volume":"54","author":"Sciacca","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejca.2017.05.041_bib10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CJI.0000000000000161","article-title":"Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder","volume":"40","author":"Chang","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2017.05.041_bib11","first-page":"11","article-title":"Myasthenia gravis and rhabdomyolysis in a patient with advanced renal cell cancer treated with nivolumab: a case report and review of the literature","volume":"2","author":"Lopez","year":"2015","journal-title":"Br J Med Health Res"},{"key":"10.1016\/j.ejca.2017.05.041_bib12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2017.05.041_bib13","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.05.041_bib14","first-page":"548","article-title":"Myasthenia gravis induced by ipilimumab in a patient with advanced melanoma","volume":"23","author":"Montes","year":"2016","journal-title":"Eur J Nuerol"},{"key":"10.1016\/j.ejca.2017.05.041_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.05.041_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mus.24648","article-title":"Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer","volume":"52","author":"Loochtan","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejca.2017.05.041_bib17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.05.041_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejca.2017.05.041_bib19","first-page":"119","article-title":"Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis","volume":"78","author":"Maeda","year":"2016","journal-title":"Nagoya J Med Sci"},{"key":"10.1016\/j.ejca.2017.05.041_bib20","article-title":"Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease","volume":"4","author":"Phadke","year":"2016","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1016\/j.ejca.2017.05.041_bib21","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mus.25055","article-title":"Myasthenia gravis exacerbation associated with pembrolizumab","volume":"54","author":"Zhu","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejca.2017.05.041_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2017.05.041_bib23","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.05.041_bib24","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejca.2017.05.041_bib25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.05.041_bib26","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.immuni.2014.11.005","article-title":"Balance and imbalance in the immune system: life on the edge","volume":"41","author":"Topalian","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2017.05.041_bib27","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ejca.2017.05.041_bib28","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/ana.20577","article-title":"A CTLA4 high genotype is associated with myasthenia gravis in thymoma patients","volume":"58","author":"Chuang","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ejca.2017.05.041_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2796.2007.01879.x","article-title":"Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis","volume":"263","author":"Wang","year":"2008","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejca.2017.05.041_bib30","doi-asserted-by":"crossref","first-page":"e101986","DOI":"10.1371\/journal.pone.0101986","article-title":"CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2017.05.041_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2016-209782","article-title":"Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases","volume":"76","author":"Calabrese","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejca.2017.05.041_bib32","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.05.041_bib33","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.51.4.933-a","article-title":"Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975","volume":"51","author":"Lindstrom","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ejca.2017.05.041_bib34","doi-asserted-by":"crossref","first-page":"mdw443","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","author":"Menzies","year":"2016","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917310171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917310171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T05:56:07Z","timestamp":1535694967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917310171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":34,"alternative-id":["S0959804917310171"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.05.041","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.05.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}